Lexaria Financial Statements From 2010 to 2024

Stocks USA . 
Stock . Lexaria Bioscience Corp
LEXXW Stock  USD 0.75  0.04  5.63%   
Lexaria Bioscience financial statements provide useful quarterly and yearly information to potential Lexaria Bioscience Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Lexaria Bioscience financial statements helps investors assess Lexaria Bioscience's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Lexaria Bioscience's valuation are summarized below:
Market Capitalization
33.8 M
Revenue
411 K
Quarterly Revenue Growth
0.081
Revenue Per Share
0.039
There are over one hundred nineteen available fundamental ratios for Lexaria Bioscience, which can be analyzed over time and compared to other ratios. All traders should should check Lexaria Bioscience's last-minute fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 115.2 M in 2024. Enterprise Value is likely to climb to about 116.4 M in 2024

Lexaria Bioscience Total Revenue

398,873

Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 132.7 K, Interest Expense of 125.2 K or Other Operating Expenses of 3.2 M, as well as many indicators such as Price To Sales Ratio of 105, Dividend Yield of 0.0 or PTB Ratio of 54.87. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Lexaria Bioscience Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets9.3 M8.9 M4.3 M
Slightly volatile
Other Current Liabilities1.1 M1.1 M214.1 K
Slightly volatile
Total Current Liabilities1.2 M1.1 M473.1 K
Very volatile
Total Stockholder Equity8.4 M8 M3.9 M
Slightly volatile
Property Plant And Equipment Net370.1 K389.6 K705.7 K
Slightly volatile
Accounts Payable1.1 M1.1 M199 K
Slightly volatile
Cash6.8 M6.5 M2.7 M
Slightly volatile
Non Current Assets Total1.3 M969.8 K954.5 K
Pretty Stable
Cash And Short Term Investments6.9 M6.6 M2.8 M
Slightly volatile
Common Stock Total Equity95.1 K90.6 K60.3 K
Slightly volatile
Common Stock Shares Outstanding13 M12.4 M6.5 M
Very volatile
Liabilities And Stockholders Equity9.3 M8.9 M4.3 M
Slightly volatile
Non Current Liabilities Total209.8 K109.3 K65.4 K
Slightly volatile
Other Current Assets1.2 M1.2 M338.3 K
Slightly volatile
Other Stockholder Equity62.6 M59.6 M27.1 M
Slightly volatile
Total Liabilities1.3 M1.2 M519.9 K
Very volatile
Property Plant And Equipment Gross1.4 M807.1 K869.8 K
Pretty Stable
Total Current Assets8.3 M7.9 M3.3 M
Slightly volatile
Common Stock8.8 K9.3 K35.4 K
Pretty Stable
Short and Long Term Debt Total130.5 K137.4 K416.3 K
Slightly volatile
Net Receivables166.2 K154.5 K167.7 K
Slightly volatile
Short Term Debt26.6 K28 K358.2 K
Slightly volatile
Intangible Assets295.9 K516.7 K208.9 K
Slightly volatile
Long Term Debt30.3 K27.6 K36.2 K
Slightly volatile
Capital Surpluse23.4 M34.9 M20.9 M
Slightly volatile
Property Plant Equipment736.9 K701.8 K299.3 K
Slightly volatile
Net Invested Capital5.4 M3.5 M4.1 M
Slightly volatile
Net Working Capital2.1 M2.2 M3.3 M
Pretty Stable
Short Term Investments53 K55.8 K105.4 K
Slightly volatile
Capital Stock6.9 K7.3 K53.8 K
Slightly volatile
Capital Lease Obligations117.9 K188.6 K124.3 K
Very volatile
Short and Long Term Debt6.3 K7.1 K7.8 K
Slightly volatile

Lexaria Bioscience Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense125.2 K102.9 K111.3 K
Pretty Stable
Other Operating Expenses3.2 M6.2 M3.6 M
Slightly volatile
Total Operating Expenses6.5 M6.2 M3.7 M
Slightly volatile
Total Revenue398.9 K464.3 K453.3 K
Pretty Stable
Cost Of Revenue4.6 K4.8 K200.5 K
Slightly volatile
Selling General Administrative2.5 M3.9 M2.7 M
Slightly volatile
Selling And Marketing Expenses154.5 K234.9 K194.8 K
Slightly volatile
Research Development1.2 M2.4 M836.6 K
Slightly volatile
Reconciled Depreciation96.1 K167.2 K58.9 K
Slightly volatile
Minority Interest99.2 K54.8 K51.2 K
Slightly volatile

Lexaria Bioscience Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow6.8 M6.5 M2.7 M
Slightly volatile
Begin Period Cash Flow1.8 M1.4 M2 M
Slightly volatile
Depreciation97 K76.2 K103.6 K
Pretty Stable
Other Non Cash Items166 K174.7 K390.7 K
Pretty Stable
Stock Based Compensation538.4 K492.2 K559.8 K
Pretty Stable
Sale Purchase Of Stock2.5 M3.1 M1.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio105104185
Slightly volatile
PTB Ratio54.876.02539.8376
Pretty Stable
Days Sales Outstanding26.35121479
Slightly volatile
Book Value Per Share0.08160.61850.8131
Pretty Stable
Average Payables68.7 K641.5 K99.3 K
Slightly volatile
Stock Based Compensation To Revenue0.751.06027.3142
Slightly volatile
Capex To Depreciation0.760.799117.0387
Slightly volatile
PB Ratio54.876.02539.8376
Pretty Stable
EV To Sales10690.5897172
Slightly volatile
Payables Turnover8.50.00461.6649
Slightly volatile
Sales General And Administrative To Revenue1.168.296843.0361
Slightly volatile
Research And Ddevelopement To Revenue3.675.08445.9634
Pretty Stable
Capex To Revenue0.07930.08351.2335
Slightly volatile
Cash Per Share0.00260.52940.5698
Pretty Stable
Days Payables Outstanding42.9480.1 K5.8 K
Slightly volatile
Intangibles To Total Assets0.05840.05830.0664
Slightly volatile
Net Debt To EBITDA4.121.10590.7398
Slightly volatile
Current Ratio0.17.183819.7342
Pretty Stable
Tangible Book Value Per Share0.08160.57670.7627
Pretty Stable
Receivables Turnover13.853.00551.9503
Slightly volatile
Graham Number0.372.6144.4207
Pretty Stable
Shareholders Equity Per Share0.08160.64890.8691
Pretty Stable
Debt To Equity0.610.01710.1141
Very volatile
Capex Per Share0.00340.00360.0384
Very volatile
Average Receivables194.3 K185.1 K170.5 K
Slightly volatile
Revenue Per Share0.04270.03750.0564
Slightly volatile
Interest Debt Per Share0.06010.01110.0186
Very volatile
Debt To Assets0.360.01550.061
Very volatile
Operating Cycle26.351211.6 K
Slightly volatile
Price Book Value Ratio54.876.02539.8376
Pretty Stable
Days Of Payables Outstanding42.9480.1 K5.8 K
Slightly volatile
Company Equity Multiplier1.71.10351.1169
Pretty Stable
Long Term Debt To Capitalization0.220.01340.0792
Slightly volatile
Total Debt To Capitalization0.380.01680.0889
Pretty Stable
Debt Equity Ratio0.610.01710.1141
Very volatile
Quick Ratio0.17.183818.4093
Pretty Stable
Net Income Per E B T1.161.00.9411
Slightly volatile
Cash Ratio0.04635.912114.3804
Pretty Stable
Days Of Sales Outstanding26.35121479
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.680.71460.9955
Slightly volatile
Price To Book Ratio54.876.02539.8376
Pretty Stable
Fixed Asset Turnover0.321.191832.5729
Very volatile
Debt Ratio0.360.01550.061
Very volatile
Price Sales Ratio105104185
Slightly volatile
Asset Turnover0.310.05240.0743
Slightly volatile
Price Fair Value54.876.02539.8376
Pretty Stable

Lexaria Bioscience Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap115.2 M48.4 M19.7 M
Slightly volatile
Enterprise Value116.4 M42.1 M17.6 M
Slightly volatile

Lexaria Fundamental Market Drivers

Cash And Short Term Investments6.6 M

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue5 K5.2 K
Total Revenue464.3 K398.9 K
Cost Of Revenue4.8 K4.6 K
Stock Based Compensation To Revenue 1.06  0.75 
Sales General And Administrative To Revenue 8.30  1.16 
Research And Ddevelopement To Revenue 5.08  3.67 
Capex To Revenue 0.08  0.08 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(12.39) 0.27 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY